What is X-trodes?
Based in Tel Aviv, Israel, X-trodes operates at the intersection of advanced materials science and digital health. The company has developed the world's first scalable, wireless Smart Skin, a wearable platform that enables continuous, medical-grade electrophysiological monitoring and analytics. By allowing patients to record complex physiological data in their natural environments, X-trodes is effectively bridging the gap between laboratory-grade diagnostics and remote patient care. This technological leap positions the company as a critical player in the evolving landscape of decentralized healthcare, where the demand for non-invasive, high-resolution monitoring tools is rapidly expanding across both research and clinical applications.
How much funding has X-trodes raised?
X-trodes has raised a total of $4.5M across 1 funding round:
Angel/Seed
$4.5M
Angel/Seed (2021): $4.5M with participation from Jeremy Coller, Welltech, and Japan Israel High Tech Ventures
Key Investors in X-trodes
Jeremy Coller
A prominent private investor known for supporting high-growth technology ventures and innovative medical solutions.
Welltech
A creative solutions firm focused on digital transformation, brand development, and supporting organizations through the complexities of the digital age.
Japan Israel High Tech Ventures
A specialized investment group dedicated to fostering cross-border technological collaboration and growth between the Japanese and Israeli innovation ecosystems.
What's next for X-trodes?
With this major enterprise-level funding, X-trodes is well-positioned to scale its operations and broaden the clinical utility of its Smart Skin platform. The strategic roadmap likely involves expanding the company's footprint in international markets, enhancing its data analytics capabilities, and pursuing further regulatory milestones to integrate its technology into standard diagnostic workflows. As the healthcare industry shifts toward proactive, data-driven patient management, X-trodes is poised to leverage its unique intellectual property to capture significant market share, transforming how clinicians interpret physiological signals in real-time.
See full X-trodes company page
